EcoDrugPlus

Vascular Endothelial Growth Factor A

Ensembl ID : ENSPNYG00000014730
Gene Symbol: VEGFA
3 Cross references
201 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSPNYG00000015303
Gene Symbol: VDR
3 Cross references
388 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSPNYG00000006182
Gene Symbol: LOC102199547
3 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like

Ensembl ID : ENSPNYG00000020498
Gene Symbol: LOC102200826
3 Cross references
190 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSPNYG00000009964
Gene Symbol: LOC102210552
3 Cross references
211 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSPNYG00000020927
Gene Symbol: LOC102203592
3 Cross references
177 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSPNYG00000021002
Gene Symbol: LOC102209744
3 Cross references
196 Possible Orthologues:

Voltage-Dependent N-Type Calcium Channel Subunit Alpha-1b-Like

Ensembl ID : ENSPNYG00000019772
Gene Symbol: LOC102199534
3 Cross references
219 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSPNYG00000015027
Gene Symbol: LOC102192500
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSPNYG00000003224
Gene Symbol: LOC102206026
3 Cross references
182 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSPNYG00000003254
Gene Symbol: LOC102206512
3 Cross references
184 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSPNYG00000023686
Gene Symbol: XDH
3 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).